Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Access here alternative investment news about Askbio Partners With Tpg And Vida Ventures
Venture Capital

Askbio Partners With Tpg And Vida Ventures

by posted 3months ago 13 views
RESEARCH TRIANGLE PARK, N. Car. & FORT WORTH, Texas & SAN FRANCISCO & BOSTON, April 11, 2019-- Asklepios BioPharmaceutical, Inc (AskBio), a developer and manufacturer of Adeno-Associated Virus (AAV) gene therapy therapeutics for underserved patient populations with rare and generally untreatable genetic disorders, announced today $235 million in funding to augment and accelerate its business. TPG Capital and Vida Ventures are investing $225 million for a minority stake in the company. As part of the transaction, AskBio’s founders and board members are co-investing $10 million.

In this article